symyoo

SYMYOO, a full service CRO and digital healthcare technology company, has officially announced the launch of Phase 1 of its SYNeRA™️ Clinical Trial Management System (CTMS). This release marks a significant step toward streamlining clinical trial operations and ensuring high-quality data through an integrated digital solution, setting a new standard for clinical trial digitization. All-in-one, … SYMYOO Officially Launches Phase 1 of Its Next-Generation Clinical Trial Management System (CTMS)

SYMYOO was selected as CRO for iTARGET-Elderly Study, a large-scale registry-based randomized controlled trial (RRCT) led by the Korean Diabetes Association (KDA). This study will compare and evaluate moderate-intensity statin therapy with an individualized LDL-C target-based therapy for the primary prevention effects of cardiovascular events in elderly patients with type 2 diabetes. The large-scale study … SYMYOO Selected as CRO for the Large-Scale RRCT “iTARGET-Elderly Study”

SYMYOO is on track to become the most digitalized CRO by integrating advanced IT solutions into its home-grown EDC/ Clinical Trial Management System, in order to streamline patient recruitment and to boost trial efficiency. By combining proprietary digital systems with expert personnel, Symyoo has successfully launched the Man-Unmanned Teaming Clinical Trial (MUM-T CT) model, driving innovation … SYMYOO, Leading the Way in Digitalized Clinical Research

As a National Coordination Center, SYMYOO conducts REMATCH study, which is a very large-scale Registry-based Randomized Clinical Trial (RRCT) sponsored by the Korea Diabetes Association (KDA). This REMATCH study aims to define optimal type 2 diabetes management strategies that will improve cardiovascular and renal outcomes in type 2 diabetes mellitus patient population. Over 60 clinical … SYMYOO Supports Korea Diabetes Association (KDA)’s large-scale RRCT, REMATCH

Smart Trial Research Center (STRC) at SYMYOO launches a new database engine, developed with multi-tier system architecture, meta-data driven and hierarchically structured database design. This SYNeRAᵀᴹ DB engine is optimized considering the systemic structural characteristics that easily reflect various system requirements from simple clinical studies to large-scale, multinational, and multi-center late-stage clinical trials, while enabling … Launch of SYNeRAᵀᴹ Platform DB Engine

Symyoo established Dodlab, Inc., to create new innovations and values under the vision ‘Making the Better Place to Live with IT Technologies’. Dodlab will pioneer new areas in the many industrial sectors, including the healthcare arena, and develop into a leading IT technology company with excellence in technology and expertise in order to help their … Dodlab, an IT Platform Company Launched

Symyoo was designated as a global coordinating center to run late phase multinational clinical trials for Covid-19 medication development. The trials are conducted widely across Korea and European countries. Symyoo understands well that the trial operations should be very specific to the risk and complexity of each region/country where the trials are conducted.

Established Symyoo America, Inc. in order to provide global trial consulting services for the Korean pharmaceutical, biotechnology and life-science companies wishing to enter the global market.

Symyoo participated in Korea CDISC Coordinating Committee (K3C) and achieved CDISC/SCDM industry partnership, which is granted to a company having comprehensive data management capability for clinical research.

Symyoo EDC system, SYNeRA™, expanded its functionalities by integrating new modules, including IWRS (Interactive Web-based Randomization System), IP Accountability (Investigational Product Tracking and Management System), and RBM (Risk-Based Monitoring System). Symyoo IWRS can handle various randomization algorithms from simple permuted block randomization to very complex covariate adaptive randomization (biased coin, minimum sufficient).